At week 52, mean percentage change in body weight compared to baseline was -10.7%, -13.3%, and -15.6% in the 5 mg, 10 mg, and 15 mg tirzepatide arms compared to -0.8% in the placebo arm
pylori, and heavy metals may be warranted
Benefits patients commonly report
Being honest about portion sizes, alcohol intake, and sedentary time will help ensure you receive the most accurate assessment and appropriate support
India is home to over 100 million people with diabetes and approximately 250 million classified as obese or overweight.[15] What makes the situation uniquely dangerous is the Thin-Fat Indian paradox: South Asians tend to accumulate more visceral (belly) fat, liver fat, and less lean muscle mass at lower body weights than Western populations.[8][9][10] While GLP-1 medications are a global phenomenon, they are particularly critical for the Thin-Fat Indian phenotype